80+ Trials Underway To Treat Covid-19
BioSpectrum Asia|April 2020
In just over 90 days of identification of a pneumonia of unknown cause, the novel coronavirus pandemic, which is raging around the world and posing a challenge for all countries and regions. As on April 2,2020 the number of confirmed COVID-19 cases worldwide has risen above 1 million, according to the new tally from Johns Hopkins University. Since the emergence of the novel coronavirus (COVID-19), biopharmaceutical companies across the world have stepped up their research efforts to develop vaccines and treatments in order to contain the virus. As of March 26, 2020, there are a number of therapeutics currently in clinical trials and more than 52 candidate vaccines are in preclinical evaluation for COVID-19 and 2 candidate vaccines are in clinical evaluation. Over 80 clinical trials are underway to test new and existing medicines across the globe.
Narayan Kulkarni
80+ Trials Underway To Treat Covid-19

At the close of 2019, i.e. on December 31 the WHO China Country Office was informed of a pneumonia of unknown cause, detected in the city of Wuhan in Hubei province, China. According to the authorities, some patients were operating dealers or vendors in the Huanan Seafood market. After 7 days the Chinese authorities identified the virus that caused the pneumonia-like illness as a new type of coronavirus (called novel coronavirus or nCoV). The first death in China due to this nCoV was recorded on January 10 even as officials confirmed a case of the novel coronavirus out of China-in Thailand-on January 13. WHO noted that it was not unexpected that cases of the novel coronavirus would emerge outside of China and reinforced why WHO calls for active monitoring and preparedness in other countries. Then it was no looking back for this novel coronavirus as it spread to over 200 countries with a total of 1,002,159 people being diagnosed across the world, a death toll of 51,485 and recovery of more than 200,000 patients as shown by the regularly updated tally of the Johns Hopkins University’s Center for Systems Science and Engineering in the US as on April 2.

Disease outbreaks present a unique opportunity for research, but this can only happen if experts in different countries share information promptly. The decision by Chinese authorities to release the genetic sequence of the newly discovered beta coronavirus for researchers worldwide exemplifies the transparency needed to tackle unfolding public health emergencies. This helped the scientists to have vital genetic data that will help speed up the development of diagnostic tests, case detection and, potentially, a vaccine.

この記事は BioSpectrum Asia の April 2020 版に掲載されています。

7 日間の Magzter GOLD 無料トライアルを開始して、何千もの厳選されたプレミアム ストーリー、8,500 以上の雑誌や新聞にアクセスしてください。

この記事は BioSpectrum Asia の April 2020 版に掲載されています。

7 日間の Magzter GOLD 無料トライアルを開始して、何千もの厳選されたプレミアム ストーリー、8,500 以上の雑誌や新聞にアクセスしてください。

BIOSPECTRUM ASIAのその他の記事すべて表示
New South Wales government injects $5M for critical research to address Silicosis crisis
BioSpectrum Asia

New South Wales government injects $5M for critical research to address Silicosis crisis

The New South Wales (NSW) government in Australia has committed $5 million in critical funding for silicosis research and a patient support programme for individuals and their families navigating the health risks associated with exposure to silica dust.

time-read
1 min  |
BioSpectrum Asia May2024
Singapore approves new asthma indication for GSK's Trelegy Ellipta
BioSpectrum Asia

Singapore approves new asthma indication for GSK's Trelegy Ellipta

GSK Singapore has announced that the Health Sciences Authority (HSA) has approved a new indication and a new strength for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol 'FF/UMEC/VI') for the maintenance treatment of asthma in patients aged 18 years and older who are not adequately controlled with a combination of a long-acting beta2-agonist (LABA) and an inhaled corticosteroid (ICS).

time-read
1 min  |
BioSpectrum Asia May2024
What's APAC's Recipe of Success in CLINICAL TRIALS MARKET?
BioSpectrum Asia

What's APAC's Recipe of Success in CLINICAL TRIALS MARKET?

Asia-Pacific APAC) is emerging as one of the most promising and resilient markets for clinical trials. According to a report by Clinical Trials Arena, between 2017 and 2022, the region posted growth in clinical trials of around 10 per cent, outstripping growth in other major regions including the US, Europe and the rest of the world RoW). Asia’s growth far exceeded the overall average figure of 5.3 per cent per year. As of 2023, the number of trials reached 14,346 in APAC. Let's delve into the thriving clinical research landscape in the region and explore the trends driving its growth.

time-read
10+ 分  |
BioSpectrum Asia May2024
From Haematologic to Autoimmune DiseaseThe CAR-T Therapy Second Revolution
BioSpectrum Asia

From Haematologic to Autoimmune DiseaseThe CAR-T Therapy Second Revolution

Cell and gene therapies have revolutionised the field of medicine, offering new treatment options for patients with various diseases that, by type of disease or severity, were considered untreatable until a few years ago. Rapid technological advancements in genetic and biological engineering and improvements in the quality and standardisation of the manufacturing process are fostering a marked increase in clinical development of these advanced therapies, generally named cell and gene therapies CGT), and they are expected to receive more approvals in the near future.

time-read
5 分  |
BioSpectrum Asia May2024
"Biotech startups still need support in terms of talent, and resources to bring their innovations to market"
BioSpectrum Asia

"Biotech startups still need support in terms of talent, and resources to bring their innovations to market"

Raymond Chow has recently stepped in as the Vice President, Asia Pacific at USheadquartered Cytiva, a global provider of technologies and services for biological therapies, formerly known as GE Healthcare Life Sciences.

time-read
5 分  |
BioSpectrum Asia May2024
"We are exploring opportunities to collaborate with startups and incubators"
BioSpectrum Asia

"We are exploring opportunities to collaborate with startups and incubators"

Agilent Technologies, a global leader in analytical and clinical laboratory technologies, has named Padraig McDonnell CEO-elect and Chief Operating Officer (COO), succeeding current President and CEO Mike McMullen.

time-read
5 分  |
BioSpectrum Asia May2024
"Australia offers a simple, supportive and robust regulatory process to initiate human trials efficiently"
BioSpectrum Asia

"Australia offers a simple, supportive and robust regulatory process to initiate human trials efficiently"

US-based Uvax Bio, LLC, a spin-off vaccine company from Scripps Research, employs proprietary 1c-SApNP platform technology invented by Dr Jiang Zhu of Scripps Research to develop and commercialise prophylactic vaccines for challenging infectious diseases.

time-read
2 分  |
BioSpectrum Asia May2024
"Regulatory encouragement of advanced tech, including AI will accelerate clinical trials in APAC"
BioSpectrum Asia

"Regulatory encouragement of advanced tech, including AI will accelerate clinical trials in APAC"

Lokavant Holdings, a US-based clinical trial intelligence technology company provides clinical trial intelligence that enables study teams to make data-driven decisions, as well as risk-based quality management and monitoring services to pharmaceutical companies and contract research organisations (CROs).

time-read
2 分  |
BioSpectrum Asia May2024
What Are the Main Challenges of Modern Clinical Trials?
BioSpectrum Asia

What Are the Main Challenges of Modern Clinical Trials?

With a cumulative total of almost 478,000 globally registered trials from the year 2000 to 2023, and growing at around 10 per cent a year in the last five years, the pharmaceutical industry continues to invest in clinical trials as the gold-standard test of therapeutic safety and efficacy. In addition, as the world’s economies and populations move in new directions, the share of non-US trials has reached 54 per cent, a trend that is likely to continue, driven by demographics and epidemiology. As the pace accelerates, trial managers and clinicians face a significant challenge: the explosive growth of data volumes. To succeed in the future, clinical trials need to increase efficiency and better utilise clinical trial data to support informed clinical and operational decision-making.

time-read
3 分  |
BioSpectrum Asia May2024
How APAC Has Turned into Clinical Trial Behemoth
BioSpectrum Asia

How APAC Has Turned into Clinical Trial Behemoth

From being a consistent participant in clinical trial conduct worldwide, the APAC has emerged as a major power. A number of causes, including the region's thriving drug development innovation and the ongoing presence of international pharmaceutical corporations conducting multiregional studies, are driving this growth.

time-read
3 分  |
BioSpectrum Asia May2024